Trackers› Clinical trials› Santiago de Compostela

Clinical trial register · Spain

Clinical Trials in Santiago de Compostela, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Santiago de Compostela

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Santander, Santiago de Compostela, Barcelona, Coslada, Girona, Madrid, Málaga, Oviedo

2026-12-16

Not yet open

Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

NCT07858123Asthma

Chiesi Farmaceutici S.p.A.

Phase 3

700

Badalona, Barcelona, Cartagena, Jerez de la Frontera, Madrid, Santiago de Compostela, Valencia

2026-11-16

Not yet open

Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma

NCT07725640Glioma, High-Grade Glioma (HGG), Surgical Resection

Batea Oncology

Not applicable

Barcelona, Madrid, Santiago de Compostela

2026-10-30

Recruiting

Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis

NCT07799116Lupus Nephritis, Lupus Nephritis (LN)

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Phase 1/2

Badalona, Santiago de Compostela, Pamplona, León, Madrid, Murcia, Salamanca, Seville

2026-09-23

Recruiting

Heart Failure in Women: Epidemiological and Prognostic Insights

NCT07847983Heart Failure

Carolina Ortiz Cortes

Observational

430

Santiago de Compostela, Donostia / San Sebastian, Úbeda, Las Palmas de Gran Canaria, Alcorcón, Boadilla del Monte, Leganés, Majadahonda

2026-09-17

Not yet open

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786Non Small Cell Lung Cancer, Respiratory Tract Neoplasm

DrugsFecal Microbiota Transplantation·Durvalumab·Paclitaxel·Carboplatin

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Granada, Santiago de Compostela, Lugo

2026-09-15

Recruiting

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193Colorectal Adenocarcinoma

DrugsVVD-133214·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 2

140

Santiago de Compostela, Barcelona, Madrid, Málaga, Valencia

2026-09-11

Not yet open

Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years

NCT07790523COVID-19, Influenza

DrugSpikevax

Tor Biering-Sørensen

Phase 4

410,000

Santiago de Compostela

2026-09-01

Not yet open

Therapeutic Contact Intensity in a Psychological Smoking Cessation Intervention With an App

NCT06900985Smoking Behaviors

University of Santiago de Compostela

Not applicable

429

Santiago de Compostela

2026-09

Not yet open

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

NCT07717099Metastatic Hormone-Sensitive Prostate Cance

DrugsRa223·Darolutamide

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 2

Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Santiago de Compostela, Valencia, Valladolid

2026-09

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335Type 2 Diabetes, Cardiovascular Risk

DrugZenagamtide

Novo Nordisk A/S

Phase 3

1,778

A Coruña, Barcelona, Móstoles, Sanlúcar de Barrameda, Santiago de Compostela, Segovia, Valencia

2026-08-24

Recruiting

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841Overweight, Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

450

Fuenlabrada, Almería, Castilleja de la Cuesta, Ferrol, Madrid, Santiago de Compostela, Seville

2026-08-12

Not yet open

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

NCT07578337Untreated, Advanced Pancreatic Cancer

DrugsNLM-001·Botensilimab·Abraxane·Nab-paclitaxel

Nelum Corp

Phase 2

Zaragoza, Barcelona, Santander, San Sebastián, Santiago de Compostela, Málaga

2026-07-15

Recruiting

Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation

NCT07566624Severe Aortic Valve Stenosis, Valvular Heart Disease, Aortic Valve Stenosis

Fundación EPIC

Observational

100

Fuencarral-El Pardo, Santiago de Compostela, Toledo

2026-07-07

Recruiting

Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

NCT07478991Acute Myeloid Leukemia, Adult

DrugsQuizartinib·Azacitidine·Venetoclax

PETHEMA Foundation

Phase 3

376

Santiago de Compostela, Hospitalet Del Llobregat, Terrassa, Jaén, Alcalá de Henares, San Sebastián de los Reyes, Málaga, Barakaldo

2026-07-02

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

A Coruña, Almería, Badalona, Barcelona, León, Madrid, Santander, Santiago de Compostela

2026-06-29

Recruiting

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066Metastatic Hormone-sensitive Prostate Cancer

DrugsApalutamide (Erleada)·Docetaxel

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 3

320

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Santander, Granada, Santiago de Compostela, Madrid, Murcia

2026-06-05

Recruiting

Video Versus Direct Laryngoscopy for Tracheal Intubation in Pediatric Surgery

NCT07495436Tracheal Intubation, Videolaryngoscopy, General Anesthesia, Difficult Airway Intubation

Hospital Clinico Universitario de Santiago

Not applicable

5,562

Santiago de Compostela

2026-06-01

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic

Apollo Therapeutics Ltd

Phase 2

280

Alicante, Badalona, La Paz, Santiago de Compostela, Zaragoza

2026-05-28

Recruiting

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

NCT07614776Neovascular Age-related Macular Degeneration, nAMD

Amgen

Phase 3

304

Navarra, Santiago de Compostela

2026-05-27

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641HR+/HER2- Breast Cancer

DrugsBGB-43395·Abemaciclib·Ribociclib·Palbociclib

BeOne Medicines

Phase 3

1,056

Elcheelx, Granada, Madrid, Santiago de Compostela, Seville

2026-05-22

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759Irritable Bowel Syndrome, Diarrhea

DrugBrenipatide

Eli Lilly and Company

Phase 2

531

Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela

2026-05-06

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela

2026-05-04

Not yet open

REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

NCT07611188Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device, LVAD

Puerta de Hierro University Hospital

Not applicable

Seville, Salamanca, Barcelona, A Coruña, Santiago de Compostela, Madrid, Majadahonda

2026-05

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772Irritable Bowel Syndrome, Constipation

DrugBrenipatide

Eli Lilly and Company

Phase 2

342

Barcelona, Centelles, Granada, Madrid, Marbella, Salamanca, Santiago de Compostela

2026-04-29

Recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232Crohn Disease

DrugsRisankizumab·Guselkumab

Janssen Research & Development, LLC

Phase 3

530

Alicante, Barcelona, Ferrol, Gijón, Girona, Madrid, Navarra, Santiago de Compostela

2026-04-21

Recruiting

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT07486960Psoriatic Arthritis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

140

Santiago de Compostela, Barcelona, Madrid, Valencia

2026-04-20

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-20

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954Diabetes Mellitus, Type 2

DrugsNNC0662-0419·Semaglutide

Novo Nordisk A/S

Phase 2

270

La Roca Del Vallés, A Estrada, Barcelona, Castilleja de la Cuesta, Girona, Santiago de Compostela

2026-04-17

Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630Obesity, Knee Osteoarthritis (OA)

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-13

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)

DrugEnpatoran

EMD Serono Research & Development Institute, Inc.

Phase 3

202

Santiago de Compostela, Valencia

2026-03-10

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

NCT07282574Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 2

360

L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Lleida, Pozuelo de Alarcón, El Palmar, Vigo, Barakaldo

2026-03-10

Recruiting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177Non-segmental Vitiligo

DrugGIA632

Novartis Pharmaceuticals

Phase 2

210

Santiago de Compostela, Barcelona, Córdoba, Madrid, Pontevedra, Seville

2026-03-09

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Seville, Valladolid

2026-03-05

By invitation

Effectiveness of Health Education as a Nursing Intervention in Improving Quality of Life and Reducing Symptoms of Anxiety and Depression in Ostomy Patients Following Digestive Surgery: A Quasi-Experimental Study.

NCT07347158Colon Cancer, Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis), Colitis Ulcerative

Hospital Clinico Universitario de Santiago

Not applicable

Santiago de Compostela

2026-03-04

Not yet open

Mineral Trioxide Aggregate (MTA) vs Gutta-Percha for Non-Surgical Endodontic Retreatment in Teeth With Apical Lesions

NCT07477171Periapical Diseases, Root Canal Therapy, Mineral Trioxide Aggregate (MTA)

University of Santiago de Compostela

Not applicable

Santiago de Compostela

2026-03

Recruiting

Occlusal Equilibration vs. Sham Therapies for TMDs: Post-Trial Follow-up (OEST)

NCT07445516Temporomandibular Disorders (TMD), Myalgia of Mastication Muscle, Arthralgia Syndrome

Urbano Santana Penin

Observational

110

Santiago de Compostela

2026-02-16

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Barcelona, Madrid, Pamplona, Santander, Santiago de Compostela, Valencia

2026-02-03

Active, closed

REGENFAST vs L-PRF in Periodontal Regeneration

NCT07430748Regeneration, Periodontal Defects, Biomaterials

University of Santiago de Compostela

Early Phase 1

Santiago de Compostela

2026-02-01

Recruiting

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003Amyotrophic Lateral Sclerosis

DrugPridopidine

Prilenia

Phase 3

500

Barcelona, Madrid, Santiago de Compostela, Valencia

2026-02-01

Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190Uveal Melanoma

DrugDarovasertib

IDEAYA Biosciences

Phase 3

520

Santiago de Compostela, L'Hospitalet de Llobregat, Pamplona, Valencia, Valladolid, Seville

2026-01-25

Recruiting

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873Arthritis, Psoriatic

Janssen Research & Development, LLC

Phase 2

240

A Coruña, Santiago de Compostela, Seville

2026-01-15

Recruiting

External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis

NCT07418099Coagulation Disorder, Blood, Prolonged APTT

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,500

Leganés, Barcelona, Lleida, Madrid, Murcia, Pamplona, Salamanca, Santiago de Compostela

2026-01-13

Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452Multiple Myeloma

DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone

AbbVie

Phase 2/3

680

Santiago de Compostela, Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, León, Madrid

2026-01-08

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Palma de Mallorca, L'Hospitalet de Llobregat, Majadahonda, Barcelona, Madrid, Santiago de Compostela, Seville, Toledo

2026-01-07

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Santiago de Compostela, Elche, Granada, Seville, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Girona

2026-01-06

Not yet open

Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis

NCT07270523Bacterial Sepsis

Complexo Hospitalario Universitario de A Coruña

Not applicable

198

Santiago de Compostela

2026-01-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Santiago de Compostela, Barcelona, Madrid, Pamplona, Badalona, Elche (alicante), Málaga, Salamanca

2025-12-31

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

1,035

Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2025-12-15

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Barcelona, Málaga, Sabadell, Santiago de Compostela, Valencia

2025-12-15

Recruiting

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249Cardiovascular Diseases

Fundación EPIC

Observational

960

Vilagarcía de Arousa, Badalona, Barcelona, León, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Seville

2025-12-11

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Santiago de Compostela, Málaga, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Madrid, Córdoba, Valencia

2025-12-11

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Santiago de Compostela, Sabadell, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2025-12-10

Recruiting

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07137598Rheumatoid Arthritis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

160

La Corua, Santiago de Compostela, Málaga, Seville

2025-12-05

Recruiting

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

110

Santiago de Compostela, Barcelona, Madrid

2025-12-04

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela, Valencia, Zaragoza

2025-12-03

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville

2025-12-03

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

366

Esplugues de Llobregat, Barcelona, Madrid, Santiago de Compostela

2025-12-03

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281Atopic Dermatitis

DrugAbrocitinib

Pfizer

Phase 3

500

Santiago de Compostela, Granollers, Zaragoza

2025-12-02

Recruiting

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232Atopic Keratoconjunctivitis

DrugDFL24498

Dompé Farmaceutici S.p.A

Phase 3

153

Córdoba, Santiago de Compostela, Valencia, Valladolid, Zaragoza

2025-12-01

Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625Acromegaly

Debiopharm International SA

Phase 3

119

Alzira, Barcelona, Madrid, Santiago de Compostela, Seville

2025-11-26

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Alicante, Badalona, Granada, Madrid, Manises, Málaga, Santiago de Compostela, Valencia

2025-11-14

Active, closed

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482Hyperlipidemia

DrugsEnlicitide·Enlicitide Decanoate·Rosuvastatin

Merck Sharp & Dohme LLC

Phase 3

996

Santiago de Compostela, Barcelona

2025-11-11

Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917Hidradenitis Suppurativa

DrugBrivekimig

Sanofi

Phase 2

208

Santiago de Compostela, Las Palmas de Gran Canaria, Manises, Cadiz, Granada, Madrid

2025-11-06

Recruiting

A Study With CIT-013 in HS Patients

NCT06993233Hidradenitis Suppurativa (HS)

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-31

Recruiting

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615Chronic Spontaneous Urticaria

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 2

200

Santiago de Compostela, Córdoba, Barcelona, Alcorcón, Valencia

2025-10-30

Recruiting

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045Pancreatic Adenocarcinoma Metastatic

DrugsOMTX705·Nab-paclitaxel·Tislelizumab·Gemcitabine

Oncomatryx Biopharma S.L.

Phase 1

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela

2025-10-28

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo

2025-10-22

Recruiting

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

NCT06971731Phenylketonuria

DrugRepinatrabit

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

120

Madrid, Santiago de Compostela

2025-10-20

Recruiting

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma

DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab

Gruppo Oncologico del Nord-Ovest

Phase 2

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2025-10-20

Active, closed

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390Arthritis, Rheumatoid

DrugsTulisokibart·Methotrexate

Merck Sharp & Dohme LLC

Phase 2

185

Sabadell, Santander, Santiago de Compostela, Barcelona

2025-10-08

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab·Visugromab RDE·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Jaén, Málaga, Seville, Barcelona, Santiago de Compostela, Girona, Logroño, Madrid

2025-10-07

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Barcelona, Gijón, Girona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-03

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Barcelona, Ferrol, Galdakao, Gijón, Girona, Madrid, Santiago de Compostela, Seville

2025-10-01

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2025-09-13

Recruiting

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244Healthy

DrugPrevnar 20

Pfizer

Phase 3

6,000

Santiago de Compostela, Esplugues de Llobregat, Pozuelo de Alarcón, Torrejón de Ardoz, Madrid, Antequera, Aravaca, Seville

2025-08-25

Recruiting

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2/3

153

Oviedo, Santiago de Compostela, Pamplona

2025-08-21

Recruiting

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone

Astellas Pharma Global Development, Inc.

Phase 2

218

Barcelona, Madrid, Santiago de Compostela

2025-08-19

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Santiago de Compostela, Seville, Esplugues de Llobregat, Bizkaia, Barcelona, Alcalá de Henares, Madrid, Pamplona

2025-08-06

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

A Coruña, Santiago de Compostela, Alcobendas, Madrid, Seville, Barcelona

2025-08-01

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja

2025-08-01

Recruiting

A Study With CIT-013 in RA Patients

NCT06567470Rheumatoid Arthritis

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

A Coruña, Barcelona, Madrid, Santander, Santiago de Compostela

2025-07-29

Recruiting

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608Fabry Disease

Chiesi Farmaceutici S.p.A.

Phase 2/3

Santiago de Compostela

2025-07-29

Recruiting

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268Eczema

DrugAbrocitinib

Pfizer

Phase 3

150

Santiago de Compostela, Granollers, Zaragoza

2025-07-24

Recruiting

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

NCT07163325Advanced Solid Tumor (Phase 1)

Epics Therapeutics

Phase 1

Barcelona, Madrid, Santiago de Compostela

2025-07-24

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)

DrugsEYLEA (aflibercept)·4D-150 IVT

4D Molecular Therapeutics

Phase 3

480

Santiago de Compostela, Barcelona, Seville

2025-07-22

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia

2025-07-21

Recruiting

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

NCT07284121Lung Cancer, Hepatocellular Carcinoma

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Observational

700

Almería, Palma de Mallorca, Manresa, Puerto Real, Alcázar de San Juan, Santiago de Compostela, Oviedo, Reus

2025-07-15

Not yet open

Vertical Soft Tissue Augmentation With Tent Pole Technique and Its Influence on Marginal Bone Loss Around Dental Implants

NCT07018531Soft Tissue Augmentation Around Dental Implants

University of Santiago de Compostela

Not applicable

112

Santiago de Compostela

2025-07

Not yet open

Osteogenic Action of a Medical Device Based on Beta-tricalcium Phosphate (BTCP)

NCT06935747Bone Loss, Regenerative Inflammation, Third Molars Extraction

Mario Pérez Sayáns

Phase 4

Santiago de Compostela, Murcia

2025-07

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

2,400

L'Hospitalet de Llobregat, Bilbao, Salamanca, Jaén, Santiago de Compostela, Pozuelo de Alarcón, Valencia, Barcelona

2025-06-30

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Barcelona, Madrid, Málaga, Santiago de Compostela

2025-06-24

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Barcelona, Santander, Santiago de Compostela

2025-06-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid, Valencia

2025-06-19

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829Knee Osteoarthritis, Synovitis of Knee

DrugLiraglutide

4Moving Biotech

Phase 2

129

A Coruña, Alicante, Sabadell, Santiago de Compostela, Seville

2025-06-17

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela

2025-06-17

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Santiago de Compostela, Granollers, Manresa, Las Palmas de Gran Canaria, Alcorcón, Majadahonda, Gijón, Seville

2025-06-17

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

573

Barcelona, Esplugues de Llobregat, Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Manises, Santiago de Compostela

2025-06-12

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Santiago de Compostela, Gijón, Lugo, Madrid, Ourense, Seville

2025-05-27

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Santiago de Compostela, Badalona, Barcelona, Santander, Cáceres, Lugo, Girona, Madrid

2025-05-22

Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine

DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab

AstraZeneca

Phase 2

150

Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Santiago de Compostela

2025-05-15

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

350

Santiago de Compostela, Las Palmas de Gran Canaria, Madrid

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Santander, Santiago de Compostela, Majadahonda Madrid, Madrid, Barcelona, Córdoba, Lugo, Seville

2025-05-13

Not yet open

Efficacy of the Vacucis Candida® Autovaccine

NCT05289375Oral Candidiasis, Oral Candidiasis Recurrent, Radiotherapy; Complications, Candida Albicans Infection

University of Santiago de Compostela

Not applicable

Santiago de Compostela

2025-04-30

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

A Coruña, Santiago de Compostela, Barcelona, Hospitalet, Palma, Madrid, Majadahonda, Pontevedra

2025-04-24

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

A Coruña, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia, Zaragoza

2025-04-09

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Santiago de Compostela, Pamplona, Córdoba, Madrid

2025-04-01

Recruiting

Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate

NCT06649357Prostate Hyperplasia, Surgery, Endoscopic Anatomical Enucleation of the Prostate (EEAP)

Fundacio Puigvert

Not applicable

130

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Santander, Gijón, Valladolid

2025-04-01

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

Santiago de Compostela, Córdoba, Madrid, Zaragoza

2025-04-01

Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant Sciences GmbH

Phase 2

162

Barcelona, Bilbao, Córdoba, Santiago de Compostela, Valencia

2025-03-18

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Santiago de Compostela, Palma, Badalona, Pamplona, Granada, Salamanca

2025-03-12

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Mérida, Sabadell, Santiago de Compostela, Málaga, Seville, Valencia

2025-03-03

Active, closed

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126Uveal Melanoma, Ocular Melanoma

DrugRoginolisib

iOnctura

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-02-27

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Santiago de Compostela, Barcelona, Jaén, Madrid, Majadahonda, Valencia, Seville

2025-02-25

Recruiting

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

NCT06828848Gram Negative Infections

DrugMeropenem

Menarini Group

Phase 2

Barcelona, Cadiz, Girona, Madrid, Málaga, Santiago de Compostela

2025-02-18

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Santiago de Compostela, Barcelona, Jerez de la Frontera, Majadahonda, Seville, Sabadell, Zaragoza

2025-02-12

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville

2025-02-04

Recruiting

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

NCT06897839Bronchopulmonary Dysplasia

Airway Therapeutics, Inc.

Phase 2/3

366

Alicante, Barcelona, Bilbao, Cadiz, Lleida, Madrid, Málaga, Santiago de Compostela

2025-02-03

Recruiting

Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry

NCT06163807Chronic Asthma

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,200

Santiago de Compostela, Badalona, Barcelona, A Coruña, Madrid, Pamplona

2025-02-01

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Barcelona, Madrid, Palma de Mallorca, Santiago de Compostela, Valencia

2025-01-30

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Vitoria-Gasteiz, Badajoz, Barcelona, Santiago de Compostela, Madrid, A Coruña, Seville, Valencia

2025-01-15

Not yet open

Non-Surgical Treatment of Peri-implantitis with Systemic Azithromycin or Placebo

NCT06715150Peri-implantitis

DrugAzithromcyin

University of Santiago de Compostela

Phase 4

Santiago de Compostela

2025-01-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

Madrid, Palma, Pamplona, Santiago de Compostela, Valencia

2025-01-02

By invitation

Effectiveness of Home-Based Exercise and Brain Stimulation for Reducing Fatigue in Patients With Multiple Sclerosis

NCT07567989Multiple Sclerosis

Jacobo Formigo

Not applicable

A Coruña, Santiago de Compostela, Vigo

2025-01-01

Active, closed

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

NCT06619509Solid Tumours

Boehringer Ingelheim

Phase 2

Aragon, Madrid, Santiago de Compostela

2024-12-30

Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612Acquired Blepharophimosis

Santen SAS

Phase 3

234

Granada, Madrid, Santiago de Compostela, Zaragoza

2024-12-30

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

A Coruña, Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Úbeda, Lugo, Madrid, Majadahonda

2024-12-19

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Barcelona, Jerez de la Frontera, Madrid, Santiago de Compostela, Valencia

2024-12-16

Not yet open

Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation

NCT06645249Atrial Fibrillation (AF)

DrugAmiodarone

Institut Investigacio Sanitaria Pere Virgili

Phase 4

122

Badalona, Barcelona, Reus, Santiago de Compostela

2024-12-10

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908Carcinoma, Non-Small-Cell Lung

DrugsJNJ-90301900·Durvalumab

Johnson & Johnson Enterprise Innovation Inc.

Phase 2

130

Madrid, Pamplona, Santiago de Compostela, Valencia

2024-12-06

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Barcelona, Cadiz, Madrid, Salamanca, Santiago de Compostela

2024-12-03

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

L'Hospitalet de Llobregat, Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Marbella, Pamplona, Alicante

2024-11-25

Active, closed

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

NCT06668805Noonan Syndrome

DrugVosoritide

BioMarin Pharmaceutical

Phase 2

Santiago de Compostela, Oviedo

2024-11-22

Active, closed

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

NCT06684743RSV

Tor Biering-Sørensen

Phase 4

690,000

Santiago de Compostela

2024-11-18

Active, closed

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

NCT06415175Atopic Dermatitis

DrugDupilumab

Sanofi

Observational

143

Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga

2024-11-14

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santiago de Compostela

2024-11-12

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga

2024-11-07

Recruiting

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593Moderately to Severely Active Crohn Disease

DrugObefazimod

Abivax S.A.

Phase 2

212

Barcelona, Córdoba, Fuenlabrada, Huelva, Las Palmas de Gran Canaria, Santiago de Compostela, Seville, Valencia

2024-10-30

Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

196

Santiago de Compostela, Valencia

2024-10-29

Recruiting

The Sagittarius Trial

NCT06490536Colon Cancer Stage II, Colon Cancer Stage III

DrugsFolinic acid·Panitumumab·Pertuzumab·Temozolomide

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 3

700

Barcelona, Valencia, Córdoba, Madrid, Pamplona, Santander, Santiago de Compostela, Zaragoza

2024-10-22

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

A Coruña, Alcobendas, Bilbao, Castelló, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela

2024-10-14

Recruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer

Fundacio Clinic Barcelona

Not applicable

304

L'Hospitalet de Llobregat, Granada, Santiago de Compostela, León, Madrid, Murcia, Reus, Bilbao

2024-10-11

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville

2024-10-10

Active, closed

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

NCT06631079Solid Tumor

NEC Bio B.V

Phase 1/2

Barcelona, Madrid, Santiago de Compostela

2024-10-07

Recruiting

European Registry of Next Generation Imaging in Advanced Prostate Cancer

NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Fundacio Puigvert

Observational

600

Barcelona, Córdoba, Madrid, San Cristóbal de La Laguna, Santander, Santiago de Compostela

2024-09-17

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Santiago de Compostela, Seville, Barcelona, Madrid, Pontevedra, Valencia

2024-09-04

Active, closed

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Tectonic Therapeutic

Phase 2

191

Barcelona, Madrid, Santiago de Compostela, Valencia

2024-09-04

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Barcelona, Córdoba, Lleida, Madrid, Pamplona, Santiago de Compostela, Seville, Valencia

2024-08-30

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

132

Santiago de Compostela, Seville, Córdoba, Madrid, Zaragoza

2024-08-27

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

NCT06625398Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

204

Santiago de Compostela, Córdoba, Madrid, Seville, Zaragoza

2024-08-27

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Santiago de Compostela, Barcelona, Majadahonda, Pamplona, Málaga, Sabadell, Santa Cruz de Tenerife, Valencia

2024-08-21

Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950Heart Failure

DrugFinerenone

Colorado Prevention Center

Phase 3

2,600

Girona, A Coruña, Santiago de Compostela, Madrid, Majadahonda, Málaga, Manises, Valencia

2024-08-20

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Burjassot, Barcelona, Santiago de Compostela, Seville, Zaragoza

2024-08-07

Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AbbVie

Phase 3

170

Santiago de Compostela, Majadahonda, Pamplona, Madrid, Seville

2024-08-05

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Málaga, Centelles, Barcelona, Figueres, A Coruña, Santiago de Compostela, Pozuelo de Alarcón, Alcorcón

2024-08-05

Active, closed

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

10,212

Santiago de Compostela, Centelles, Vic, Majadahonda, Alcorcón, Barcelona, Madrid, Valencia

2024-08-01

By invitation

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

NCT06475742Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

680

Sabadell, Santiago de Compostela, Seville, Valladolid

2024-07-30

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Valencia, Barcelona, Córdoba, Madrid, Majadahonda, Sant Cugat del Vallès, Santiago de Compostela, Seville

2024-07-30

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Santiago de Compostela, Elche, Granada, Palma, Barcelona, Majadahonda, El Palmar, Pamplona

2024-07-16

Recruiting

Small Macular Holes Treated With Air

NCT06211907Macular Holes

Helse Stavanger HF

Not applicable

132

Santiago de Compostela

2024-07-14

Active, closed

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

109

Santiago de Compostela, Barcelona, Bilbao, Majadahonda, Pamplona, Oviedo, Sabadell, Santa Cruz de Tenerife

2024-07-12

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746Heart Failure

DrugsFinerenone·Dapagliflozin

Colorado Prevention Center

Phase 3

1,500

A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona

2024-07-09

Recruiting

Personalized Treatment of Refractory BPPV

NCT06725966Benign Paroxysmal Positional Vertigo, Personalized Medicine

Hospital Clinico Universitario de Santiago

Not applicable

Santiago de Compostela

2024-07-01

Active, closed

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424Alpha 1-Antitrypsin Deficiency, Emphysema

Sanofi

Phase 2

185

Santander, Madrid, Santiago de Compostela

2024-06-20

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela

2024-06-17

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

LHospitalet de Llobregat, Santiago de Compostela, Huelva, Seville

2024-06-11

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville

2024-06-10

By invitation

Prostate Cancer Awareness and Initiative for Screening in the European Union

NCT06424275Prostate Cancer

European Association of Urology Research Foundation

Observational

20,000

Santiago de Compostela, Manresa

2024-06-01

Recruiting

Immunological Characteristics of Preclinical IBD

NCT05698745Crohn Disease, Ulcerative Colitis, IBD

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Observational

450

Santiago de Compostela, Badalona, Manresa, Terrassa, Donostia / San Sebastian, Vigo, Gijón, Oviedo

2024-06-01

Not yet open

Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease

NCT06421363Ischemic Heart Disease, Acute Coronary Syndrome

DrugInclisiran

Jose Seijas Amigo

Phase 4

A Estrada, Ames, Ribeira, Santiago de Compostela, Melide, Pontevedra

2024-06-01

Active, closed

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma

DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax

Janssen Research & Development, LLC

Phase 2

333

Barcelona, Córdoba, Madrid, Santander, Santiago de Compostela

2024-05-30

Recruiting

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

NCT07717268Prostatic Neoplasms, Castration-Resistant

DrugsZytiga·Xtandi

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Phase 2

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Bilbao, Salamanca, Valladolid, Terrassa, Santiago de Compostela

2024-05-16

Recruiting

Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU

NCT06322719Acute Respiratory Failure, Intubation, Intubation; Difficult or Failed, Videolaryngoscopy

Hospital Clinico Universitario de Santiago

Not applicable

1,036

Santiago de Compostela, A Coruña, Albacete, Barcelona, Cáceres, Denia, Elche, Gijón

2024-05-01

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Barcelona, Madrid, Santiago de Compostela, Seville

2024-04-30

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alicante, Barcelona, Madrid, Zaragoza

2024-04-29

Recruiting

Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)

NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections

Biobizkaia Health Research Institute

Observational

1,500

A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos

2024-04-26

Active, closed

Validation of a Life Stories Methodologies in Long-Term Care Centres

NCT06569628Long-term Care Centres for Old Adults Users, Relatives of Long-term Care Centres for Old Adults Users, Long-term Care Centres for Old Adults Professionals

Envita Digital Solutions S.L.

Not applicable

378

Santiago de Compostela, Vigo

2024-04-25

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Alicante, Barcelona, Lleida, Madrid, Santiago de Compostela, Valencia

2024-04-16

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

A Coruña, Seville, Barcelona, L'Hospitalet de Llobregat, Barakaldo, Santiago de Compostela, Donostia / San Sebastian, Salt

2024-04-16

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438Non-Small Cell Lung Cancer

DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

840

Santiago de Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2024-04-10

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

L'Hospitalet de Llobregat, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Barcelona, Madrid

2024-04-03

Active, closed

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

NCT06200207Heart Failure, Systemic Inflammation

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

673

Castilleja de la Cuesta, Salamanca, Majadahonda, Madrid, Sanlúcar de Barrameda, Santiago de Compostela, Seville, Valencia

2024-04-01

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Santiago de Compostela, Pamplona, Madrid, Seville

2024-03-23

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

El Palmar, Donostia / San Sebastian, Barcelona, Córdoba, Madrid, Santiago de Compostela, Valencia

2024-03-18

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pontevedra, Santander, Santiago de Compostela

2024-03-13

Active, closed

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

NCT06348199Non-small Cell Lung Cancer Stage IV

DrugsKeytruda·Pembrolizumab

Samsung Bioepis Co., Ltd.

Phase 3

555

Leganés, Málaga, Ourense, Oviedo, Santiago de Compostela, Seville, Valencia

2024-03-12

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

731

Alcorcón, Badalona, Barcelona, Manises, Salamanca, Santiago de Compostela, Seville, Villajoyosa

2024-03-09

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda

2024-02-20

Recruiting

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

NCT06099119Unresectable Pancreatic Cancer

Hospital Clinico Universitario de Santiago

Phase 4

100

Santiago de Compostela, Pamplona

2024-02-20

By invitation

Surveillance of Suicide Ideation in Adolescents (VISIA)

NCT06341634Suicide, Distress, Emotional, Adolescent Behavior, Healthy

Servicio Gallego de Salud

Observational

339

Santiago de Compostela, Vigo, Ourense

2024-02-06

Active, closed

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

200

Santiago de Compostela, Málaga, Palma de Mallorca, Oviedo, Barcelona, Madrid, Seville, Valencia

2024-02-01

Active, closed

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

Santiago de Compostela, Granada, Palma Mallorca, Badalona, Santander, Pozuelo de Alarcón, El Palmar, Pamplona

2024-01-30

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Barcelona, Las Palmas de Gran Canaria, Madrid, Pamplona, San Sebastián, Santander, Santiago de Compostela, Valencia

2024-01-24

Active, closed

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426Parkinson's Disease (PD)

AbbVie

Observational

427

Santiago de Compostela, Elche, Majadahonda, Granada, Madrid, Seville

2024-01-24

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Barcelona, Sant Cugat del Vallès, Santiago de Compostela, Madrid, Majadahonda, Pozuelo de Alarcón, Málaga, Pamplona

2024-01-18

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Villamartín, Zaragoza, Badalona, Sanlúcar de Barrameda, A Coruña, Santiago de Compostela, Pamplona, Barcelona

2024-01-17

Not yet open

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

NCT06097455Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

Fundacion Clinic per a la Recerca Biomédica

Early Phase 1

Santiago de Compostela, Barcelona, Madrid, Murcia, Oviedo, Palma de Mallorca, Salamanca

2024-01-15

Recruiting

GlycOxiTOD: Multimodal Vascular and Target-Organ Damage Registry

NCT06325800Hypertension, Target Organ Damage, Heart Disease Risk Factors, Vascular Stiffness

Complejo Hospitalario Universitario de Santiago

Observational

1,000

Santiago de Compostela

2024-01-10

By invitation

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315Wheezing, Asthma

DrugDupilumab

Sanofi

Phase 3

Santiago de Compostela, Barcelona, Esplugues de Llobregat, Sabadell, Jerez de la Frontera, Madrid, Valencia

2024-01-03

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga

2023-12-31

Recruiting

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

NCT06247085Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

Barcelona, Madrid, Santiago de Compostela, Seville

2023-12-28

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Santiago de Compostela, Palma, L'Hospitalet de Llobregat, Santander, Pozuelo de Alarcón, Oviedo, Barcelona, Granada

2023-12-28

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia

2023-12-21

Recruiting

Observational Study Protocol: LIVER-R

NCT06252753Hepatobiliary Cancers

AstraZeneca

Observational

4,000

Santiago de Compostela, Zaragoza, Poniente Sur, Santander, Burgos, Ourense, Majadahonda, El Palmar

2023-12-20

Active, closed

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome

NS Pharma, Inc.

Phase 2

Santiago de Compostela, Pamplona

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Barcelona, Córdoba, Madrid, Pamplona, Santiago de Compostela, Zaragoza

2023-12-20

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

904

Santiago de Compostela, Seville, Palma, Badalona, Sabadell, Terrassa, Santander, A Coruña

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón

2023-12-12

Active, closed

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma

DrugBel-sar

Aura Biosciences

Phase 3

108

Barcelona, Santiago de Compostela, Seville, Valencia

2023-12-06

Active, closed

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

NCT06282978Multiple Myeloma in Relapse

DrugElranatamab

PETHEMA Foundation

Phase 2

Santiago de Compostela, Palma de Mallorca, Badalona, Santander, Jerez de la Frontera, Las Palmas de Gran Canaria, El Palmar, Barcelona

2023-11-23

Recruiting

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010Influenza

DrugBaloxavir Marboxil

Hoffmann-La Roche

Phase 3

1,100

Santiago de Compostela, Madrid, Valencia

2023-11-22

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Santiago de Compostela, Seville, Zaragoza

2023-11-14

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Córdoba, Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Barcelona, Valencia, Zaragoza

2023-11-08

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville, Valencia

2023-10-31

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms

Drugs177Lu-edotreotide·Everolimus

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

170

Seville, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Oviedo, Valencia, Barcelona

2023-10-27

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Badalona, Barcelona, Santander, Santiago de Compostela, Málaga, Madrid, Majadahonda, Oviedo

2023-10-25

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Barcelona, Pamplona, Madrid, Santiago de Compostela, Valencia

2023-10-20

Active, closed

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

684

Alcorcón, Alicante, Barcelona, Bilbao, Madrid, Palma de Mallorca, Santiago de Compostela, Seville

2023-10-12

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia

2023-10-10

Active, closed

Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP)

NCT06053775Depressive Symptoms, Cognitive Impairment

University of Santiago de Compostela

Not applicable

Santiago de Compostela, Vigo

2023-09-27

Recruiting

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

NCT06180993RSV Infection

DrugNirsevimab

Federico Martinón Torres

Observational

42,000

Santiago de Compostela

2023-09-25

Active, closed

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610High-Risk de Novo Multiple Myeloma

DrugsTalquetamab·Teclistamab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Murcia, Pamplona, Salamanca, Santander, Santiago de Compostela

2023-09-21

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Santiago de Compostela, Vitoria-Gasteiz, Palma, Palma Mallorca, Badalona, Terrassa, Santander, León

2023-09-18

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Santiago de Compostela, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Seville, Valencia

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Santander, Santiago de Compostela, Madrid, Majadahonda, Barcelona, Girona, Oviedo, Pamplona

2023-09-14

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Mérida, Santander, San Cristóbal de La Laguna, A Coruña, Santiago de Compostela, Seville

2023-09-11

Recruiting

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

NCT06055504Non-ischemic Dilated Cardiomyopathy

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Not applicable

900

Santiago de Compostela, L'Hospitalet de Llobregat, Sabadell, A Coruña, Majadahonda, Oviedo, Alicante, Barcelona

2023-09-06

Recruiting

Brief Problem-solving Intervention in Different Formats for the Prevention of Suicide in Adults Over 50

NCT06338904Suicide

University of Santiago de Compostela

Not applicable

212

Santiago de Compostela

2023-09-01

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269Rheumatoid Arthritis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

420

Bilbao, Santiago de Compostela, Córdoba

2023-08-31

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,772

Badalona, Barcelona, Córdoba, Madrid, Sabadell, Santiago de Compostela, Seville, Valencia

2023-08-30

Active, closed

S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

NCT05243836Myopia

nthalmic Pty Ltd

Not applicable

441

Terrassa, Santiago de Compostela, Madrid

2023-08-04

Active, closed

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004Pneumonia, Bacterial

Eagle Pharmaceuticals, Inc.

Phase 2

276

Barcelona, Madrid, Santiago de Compostela, Tarragona, Terrassa, Toledo, Valencia, Valladolid

2023-07-22

Recruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831Endometrial Cancer

DrugNavtemadlin

Kartos Therapeutics, Inc.

Phase 2/3

268

A Coruña, Barcelona, Galdakao, Jaén, Jerez de la Frontera, Las Palmas, León, Santiago de Compostela

2023-07-17

Active, closed

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767Advanced Non-Small Cell Lung Cancer

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2/3

149

Santiago de Compostela, Palma, Barcelona, Majadahonda, Oviedo, Madrid, Málaga, Seville

2023-06-30

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

DrugAstegolimab

Hoffmann-La Roche

Phase 3

2,000

Mérida, Palma de Mallorca, Santander, Santiago de Compostela, Torrejón de Ardoz, Benalmádena Costa, Alzira, Barcelona

2023-06-28

Active, closed

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05672576Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

451

Alcobendas, Barcelona, Colmenar Viejo, Madrid, Santiago de Compostela, Seville, Valencia, Valladolid

2023-06-26

Active, closed

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

NCT05817942Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Observational

509

Barcelona, Badalona, Las Palmas de Gran Canaria, Palma de Mallorca, Santiago de Compostela

2023-06-12

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Majadahonda, El Palmar, Vigo, Huelva, Madrid

2023-06-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

L'Hospitalet de Llobregat, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Cáceres, Madrid, Málaga, Murcia

2023-06-07

Active, closed

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Carcinoma, Non-Small-Cell Lung

DrugsMontelukast·Lazertinib·Amivantamab·Methotrexate

Janssen Research & Development, LLC

Phase 2

Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Málaga, Palma de Mallorca, Santiago de Compostela

2023-05-18

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Santiago de Compostela, Barcelona, Esplugues de Llobregat, Madrid, El Palmar, Seville, Valencia

2023-05-17

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Barcelona, Bilbao, Córdoba, Elche, Jaén, Madrid, Salamanca, Santiago de Compostela

2023-05-08

Active, closed

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

NCT05755711Coronary Artery Disease

Shockwave Medical, Inc.

Observational

399

Santiago de Compostela, Barcelona, Córdoba, Madrid

2023-05-03

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Alicante, Barcelona, Bilbao, Córdoba, Madrid, Santander, Santiago de Compostela, Seville

2023-04-05

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Santiago de Compostela, Santander, Barcelona, Cadiz, Madrid, Málaga, Murcia, Seville

2023-04-03

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

Santiago de Compostela, Barcelona, Madrid, Seville, Valencia

2023-02-21

Active, closed

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015Metastatic Non-small Cell Lung Cancer

DrugsPegylated filgrastim·Pembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol

Merck Sharp & Dohme LLC

Phase 3

377

Santiago de Compostela, Madrid, Barcelona, Huelva

2023-02-14

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Fuenlabrada, Barcelona, Girona, Huelva, Madrid

2023-01-16

Active, closed

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013Crohn Disease, Colitis, Ulcerative

DrugDuvakitug

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

247

Huelva, Santiago de Compostela, Valencia

2023-01-11

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Santiago de Compostela, Sabadell, Barcelona, Córdoba

2022-12-16

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Madrid, Badajoz, Barcelona, Cáceres, Murcia, Santiago de Compostela

2022-12-08

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Barcelona, Majadahonda, Murcia, Santiago de Compostela

2022-11-30

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Palma de Mallorca, Granollers, L'Hospitalet de Llobregat, Ferrol, Santiago de Compostela, Logroño, Las Palmas de Gran Canaria, Marbella

2022-11-21

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Santiago de Compostela, Badalona, L'Hospitalet Del Llobregat, Terrassa, Santander, Barcelona, Girona, Madrid

2022-11-10

Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

NCT05547321Advanced Solid Tumor

DrugsOMTX705·Tislelizumab·Pembrolizumab

Oncomatryx Biopharma S.L.

Phase 1

150

Barcelona, L'Hospitalet de Llobregat, Santiago de Compostela, San Sebastián, Madrid, Pamplona

2022-10-20

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Santiago de Compostela, Aravaca, Barcelona, Granada, Madrid, Seville, Valencia

2022-10-14

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Barcelona, Madrid, Oviedo, Santander, Santiago de Compostela

2022-09-08

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Santiago de Compostela, Palma de Mallorca, L'Hospitalet de Llobregat, Málaga, Oviedo, Barcelona, Granada, Madrid

2022-09-06

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Córdoba, Madrid, El Palmar, Barcelona, Pamplona, Santiago de Compostela, Valencia

2022-08-31

Active, closed

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

NCT04936685Meningococcal Immunisation, Healthy Volunteers

Sanofi Pasteur, a Sanofi Company

Phase 3

209

Santiago de Compostela, Madrid, Seville

2022-08-23

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca

2022-08-17

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Santiago de Compostela, Boadilla del Monte, Esplugues de Llobregat

2022-08-10

Active, closed

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030Colorectal Cancer

DrugsM9140·Folinic acid·Adrucil·Capecitabine

EMD Serono Research & Development Institute, Inc.

Phase 1

220

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2022-08-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Sant Andreu de la Barca, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Granada, Huelva, Madrid, Málaga

2022-07-18

Active, closed

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446Metastatic Colorectal Cancer

DrugsEncorafenib·Erbitux·Cetuximab·Keytruda

Pfizer

Phase 2

108

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza

2022-07-11

Active, closed

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613Erosive Esophagitis

DrugNexium

AstraZeneca

Phase 3

Badalona, Santiago de Compostela, Seville

2022-07-01

Active, closed

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

529

A Coruña, Córdoba, Málaga, Santiago de Compostela, Seville, Valencia

2022-06-30

Recruiting

Cardio-Oncology Rehabilitation Care Process

NCT06302634Cardio-Oncology, Rehabilitation, Cardiovascular Diseases, Exercise

Hospital Clinico Universitario de Santiago

Observational

300

Santiago de Compostela

2022-06-22

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189Non-Small Cell Lung Cancer

DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib

BioNTech SE

Phase 1

320

Badalona, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2022-06-17

Recruiting

Flexible Tip Bougie vs Tube With Stylet for Intubation With Videolaryngoscopy.

NCT05429125Intubation; Difficult or Failed

Hospital Clinico Universitario de Santiago

Not applicable

140

Santiago de Compostela

2022-06-17

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Rincón de la Victoria, Santiago de Compostela

2022-05-30

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2022-05-23

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville

2022-05-16

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Majadahonda, Bilbao, Barcelona, Madrid, Málaga

2022-05-03

Active, closed

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

NCT05346224Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer

DrugPertuzumab

Shanghai Henlius Biotech

Phase 3

900

Santiago de Compostela, Barcelona

2022-04-25

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Barcelona, Girona, Madrid, Marbella, Santiago de Compostela, Valencia

2022-04-19

Active, closed

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

NCT05201547Endometrial Cancer

DrugsCarboplatin/Paclitaxel·Dostarlimab

ARCAGY/ GINECO GROUP

Phase 3

260

Elche, Badalona, Córdoba, León, Palma, Palma de Mallorca, Santiago de Compostela, Valencia

2022-04-15

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Barcelona, El Palmar, Madrid, Santiago de Compostela, Seville, Zaragoza

2022-04-14

Active, closed

Tissue Level vs Bone Level Implants for Plural Restorations : a Multicentre Randomised Controlled Trial

NCT05223387Dental Implants, Edentulous

Anthogyr

Not applicable

Barcelona, Santiago de Compostela

2022-03-30

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Santiago de Compostela, Barcelona, L'Hospitalet Del Llobregat, Terrassa, Badalona, Salamanca, Pozuelo de Alarcón, Madrid

2022-03-25

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Barcelona, Madrid, Santiago de Compostela

2022-03-08

Active, closed

Peri-implant Tissues on the Galimplant Anti-rotational Slim Abutment.

NCT05118815Teeth Absent, Tooth-loss, Tooth Extraction, Dental Implant

University of Santiago de Compostela

Not applicable

Santiago de Compostela

2022-02-21

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2022-02-07

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Santiago de Compostela, L'Hospitalet de Llobregat, Córdoba, Las Palmas de Gran Canaria, Majadahonda, Barcelona, Madrid

2022-01-13

Recruiting

C-MAC Videolaryngoscopy Versus Direct Laryngoscopy for Percutaneous Tracheostomy

NCT05416489Intubated Patients, Percutaneous Tracheostomy

Hospital Clinico Universitario de Santiago

Not applicable

Santiago de Compostela

2022-01-01

Active, closed

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226Neuroendocrine Tumors

DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin

ITM Solucin GmbH

Phase 3

259

Barcelona, Madrid, Oviedo, Santiago de Compostela, Valencia

2021-12-21

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Santiago de Compostela, Cadiz, Córdoba, Badalona, Barcelona, L'Hospitalet Del Llobregat, Mataró, León

2021-12-20

Active, closed

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Phase 3

Santiago de Compostela

2021-12-17

Recruiting

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

NCT04924868Acute Pancreatitis Due to Gallstones

DrugUrsodeoxycholic Acid

Hospital General Universitario de Alicante

Phase 3

332

Santiago de Compostela, Alicante, Elche, Barcelona, L'Hospitalet de Llobregat, Sabadell, Santander, Granada

2021-11-10

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

A Coruña, Badalona, Barcelona, Santiago de Compostela

2021-11-07

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

Palma de Mallorca, Santiago de Compostela, Madrid, Majadahonda, Pamplona, Valencia

2021-10-27

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville

2021-10-13

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Santiago de Compostela, L'Hospitalet Del Llobregat, Terrassa, Santander, Pamplona, Toledo, Barcelona, Girona

2021-10-04

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-09-23

Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer

Guardant Health, Inc.

Observational

2,285

A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela

2021-09-07

Active, closed

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

NCT04827953Pancreatic Ductal Adenocarcinoma

DrugsNLM-001·Zalifrelimab·Nab-paclitaxel·Gemcitabine

Nelum Corp

Phase 1/2

Santiago de Compostela, Málaga, Zaragoza, Donostia / San Sebastian, Barcelona, Santander

2021-09-01

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Elche, Palma de Mallorca, Badalona, Manresa, Sabadell, Santiago de Compostela, Jerez de la Frontera, Castellon de LA Plana/castello de LA Plana

2021-08-27

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Badalona, Santiago de Compostela, Madrid, Oviedo, Barcelona

2021-08-18

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Barcelona, Cáceres, Córdoba, Granada, Madrid, Málaga, Santiago de Compostela, Valencia

2021-06-28

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

A Coruña, Córdoba, Madrid, Málaga, Móstoles, Murcia, San Sebastián de los Reyes, Santiago de Compostela

2021-06-17

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-06-08

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Barcelona, Madrid, Pamplona, Santiago de Compostela, Valencia

2021-05-21

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04949282Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera

Sociedad Española de Medicina Nuclear e Imagen Molecular

Observational

5,000

Santiago de Compostela, Granada, Palma de Mallorca, L'Hospitalet de Llobregat, Getafe, Majadahonda, El Palmar, Pamplona

2021-05-10

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Barcelona, Granada, Lleida, Madrid, Málaga, Pamplona, Santiago de Compostela

2021-05-10

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774Spasticity

DrugsDysport·Corabotase

Ipsen

Phase 1/2

240

A Coruña, Barcelona, Huelva, Madrid, Santiago de Compostela, Seville, Vigo

2021-04-29

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Lenvatinib·Atezolizumab

Hoffmann-La Roche

Phase 3

557

Palma de Mallorca, Santiago de Compostela, Pamplona/iruña, Córdoba, Madrid, Valencia, Zaragoza

2021-04-26

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Badalona, Manresa, Girona, Santiago de Compostela, Las Palmas de Gran Canaria, Oviedo, Valencia, Barcelona

2021-04-21

Active, closed

Locoregional Control With Radiotherapy of Breast Cancer Patients With MACrometastases Treated With MAstectomy (MACMA)

NCT06378294Breast Cancer

University Hospital A Coruña

Observational

Ferrol, Santiago de Compostela, Vigo, A Coruña, Lugo, Ourense, Pontevedra

2021-04-20

Active, closed

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Lenalidomide·Dexamethasone

PETHEMA Foundation

Phase 2

Palma de Mallorca, Santander, Salamanca, Santiago de Compostela, Madrid, Gijón, Valencia, Las Palmas de Gran Canaria

2021-04-07

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

L'Hospitalet de Llobregat, Toledo, Santiago de Compostela, Pozuelo de Alarcón, Madrid, Albacete, Barcelona, Cáceres

2021-03-09

Recruiting

Role of the Dentist in the Control of the Alcoholic Habit in Patients with Potentially Malignant Oral Lesions

NCT04584333Oral Potentially Malignant Disorders, Alcohol Drinking

University of Santiago de Compostela

Not applicable

206

Santiago de Compostela

2021-03-01

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Salamanca, Santiago de Compostela, Seville

2021-02-25

Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267Amyotrophic Lateral Sclerosis

DrugsMasitinib·Riluzole

AB Science

Phase 3

495

Alicante, Barcelona, Madrid, Santiago de Compostela, Valencia

2021-02-02

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Barcelona, Madrid, Seville, Valencia, Zaragoza

2020-12-21

Active, closed

ACURATE neo2™ Post Market Clinical Follow up Study

NCT04655248Aortic Valve Stenosis, Aortic Valve Calcification, Aortic Diseases

Boston Scientific Corporation

Observational

250

Santiago de Compostela, Valladolid

2020-12-16

Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

DrugsUbamatamab·Sarilumab·Cemiplimab

Regeneron Pharmaceuticals

Phase 1/2

612

Santiago de Compostela, Girona, Madrid

2020-12-08

Active, closed

"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"

NCT05304754High-risk Leukemias

Instituto de Investigación Hospital Universitario La Paz

Phase 1/2

Santiago de Compostela, Oviedo, Barcelona, Madrid, Málaga, Murcia, Seville, Valencia

2020-11-30

Active, closed

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Bayer

Phase 4

654

Santiago de Compostela, Palma de Mallorca, Badalona, Castellon, Majadahonda, Oviedo, A Coruña, Barcelona

2020-11-09

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma

DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate

Exelixis

Phase 3

575

Elche, Palma de Mallorca, Manresa, Santiago de Compostela, Alcorcón, Oviedo, Badalona, Barcelona

2020-10-19

Recruiting

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic

Inmunotek S.L.

Phase 3

150

Santiago de Compostela, Elche, Torrevieja, Valencia, Algeciras, Jerez de la Frontera, Cartagena, Vigo

2020-10-06

Active, closed

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

NCT04293393Early Breast Cancer

DrugsLeuprolide·Goserelin·Pegylated liposomal doxorubicin·Abemaciclib

Spanish Breast Cancer Research Group

Phase 2

200

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Castellon, San Sebastián, Vigo, A Coruña, Alicante

2020-10-02

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Ferrol, Santiago de Compostela, Badalona, L'Hospitalet de Llobregat, Fuenlabrada, Majadahonda, Oviedo, Alicante

2020-09-30

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

NCT04432584Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

190

Badalona, Santiago de Compostela, Asturias, Bilbao, Barcelona, Madrid, Málaga, Salamanca

2020-09-30

By invitation

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A

Ultragenyx Pharmaceutical Inc

Phase 3

Barcelona, Santiago de Compostela

2020-09-28

Active, closed

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094Advanced Solid Tumors, HER2-positive Breast Cancer

DrugZN-A-1041

Hoffmann-La Roche

Phase 1/2

210

Argentona, Santiago de Compostela, A Gudiña, Las Cabezas de San Juan, Barcelona, Jaén, Madrid, Seville

2020-09-03

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

A Coruña, Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Oviedo, Barcelona, Granada, Madrid

2020-08-31

Active, closed

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210Multiple Myeloma

DrugsBelantamab mafodotin·Dexamethasone

GlaxoSmithKline

Phase 3

325

Barcelona, L'Hospitalet de Llobrega, Málaga, PamplonaNavarra, Pozuelo de AlarcOn Madr, Santiago de Compostela

2020-04-02

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944Non-Small Cell Lung Cancer

DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

261

Palma de Mallorca, Badalona, Santiago de Compostela, Las Palmas de Gran Canaria, Majadahonda, Pamplona, Alicante, Barcelona

2020-02-17

Active, closed

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

NCT04183166Squamous Cell Carcinoma of Head and Neck

Transgene

Phase 1/2

Barcelona, Madrid, Málaga, Santiago de Compostela

2019-12-12

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy

DrugsDinutuximab Beta·Vindesine·Cyclophosphamid·Thiotepa

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

800

Balea, Barcelona, Cruces, El Palmar, Madrid, Málaga, San Sebastián, Santiago de Compostela

2019-11-05

Active, closed

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

NCT04090736Leukemia, Myeloid, Acute

DrugAzacitidine

PETHEMA Foundation

Phase 3

302

Santiago de Compostela, Vitoria-Gasteiz, Badalona, Hospitalet Del Llobregat, San Sebastián, Jaén, Las Palmas de Gran Canaria, Pozuelo de Alarcón

2019-09-24

Active, closed

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma

DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed

Genmab

Phase 1/2

350

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona, Santiago de Compostela

2019-09-17

Recruiting

Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)

NCT03711110Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

Not applicable

514

Santiago de Compostela, Galdakao, Barcelona, Córdoba, Madrid, Málaga, Salamanca, Seville

2019-08-02

Active, closed

Functional Assessment in Elderly MI Patients With Multivessel Disease

NCT03772743Myocardial Infarction

Consorzio Futuro in Ricerca

Not applicable

1,445

A Coruña, Ciudad Real, Lugo, Madrid, Santiago de Compostela, Valencia, Valladolid, Vigo

2019-07-15

Active, closed

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

NCT03878446Short Stature Children Born Small for Gestational Age (SGA)

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 2

Esplugues Llobregat(Barcelona), Santiago de Compostela

2019-07-04

Active, closed

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219Renal Cell Carcinoma

DrugsCabozantinib·Yervoy·Ipilimumab·Opdivo

Exelixis

Phase 3

855

Santiago de Compostela, Pamplona, Barcelona, Córdoba, Madrid, Oviedo, Valencia

2019-06-25

Active, closed

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417Dermatitis Atopic

DrugDupilumab

Sanofi

Observational

955

Bilbao, Las Palmas de Gran Canaria, Majadahonda, Oviedo, Barakaldo, Barcelona, Madrid, Santiago de Compostela

2019-06-11

Active, closed

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141Pediatric Epileptic Syndrome, Partial-onset Seizures

DrugPerampanel

Eisai Inc.

Phase 2

100

Madrid, Pamplona, Santiago de Compostela, Seville

2019-05-31

Active, closed

Childhood Obesity Risk Assessment Longitudinal Study

NCT06317883Child Obesity

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Observational

1,508

Santiago de Compostela, Pamplona, Barcelona, Córdoba, Granada, Tarragona, Valencia, Zaragoza

2019-05-27

Recruiting

Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)

NCT03894228Inflammatory Bowel Diseases, Pregnancy

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Observational

1,750

Santiago de Compostela, Córdoba, Granada, Huelva, Málaga, Seville, Huesca, Zaragoza

2019-05-21

Active, closed

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer

DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab

Exelixis

Phase 1

325

Sabadell, Santiago de Compostela, Barcelona, Madrid, Seville

2019-03-20

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, San Sebastián, Santiago de Compostela, Seville

2019-03-06

Active, closed

Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

NCT03720704Peripheral Vascular Diseases

W.L.Gore & Associates

Observational

280

Oviedo, Santiago de Compostela

2018-12-18

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Barcelona, Madrid, Seville

2018-12-17

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

DrugLutathera

Advanced Accelerator Applications

Observational

1,014

Santiago de Compostela, Majadahonda

2018-11-28

Active, closed

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

NCT03602859Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

DrugsNiraparib·Dostarlimab

Tesaro, Inc.

Phase 3

1,400

Ávila, Badalona, Barcelona, Girona, Jaén, Madrid, Santiago de Compostela, Toledo

2018-10-11

Active, closed

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536Non-small Cell Lung Cancer

DrugTelisotuzumab vedotin

AbbVie

Phase 2

270

Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alcorcón, Ávila, Barcelona, Madrid, Málaga

2018-10-10

Active, closed

Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

NCT03636438Ornithine Transcarbamylase (OTC) Deficiency

Ultragenyx Pharmaceutical Inc

Observational

Santiago de Compostela, Barakaldo

2018-08-30

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Palma, Palma de Mallorca, L'Hospitalet de Llobregat, San Sebastian- Donostia, Santander, Badalona, Barcelona, Santiago de Compostela

2018-08-21

Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer

DrugsUbamatamab·Sarilumab·Cemiplimab·Tocilizumab

Regeneron Pharmaceuticals

Phase 1/2

890

Pamplona, Badalona, Barcelona, Madrid, Santiago de Compostela

2018-05-21

Active, closed

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846Urinary Bladder Neoplasms

DrugsOlaparib·Durvalumab

AstraZeneca

Phase 2

154

Barcelona, Madrid, Málaga, Santiago de Compostela

2018-03-16

Recruiting

MEditerranean LIfestyle in Pediatric Obesity Prevention

NCT04597281Obesity, Childhood

Luis A. Moreno Aznar

Not applicable

738

Córdoba, Santiago de Compostela, Zaragoza

2018-03-01

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Sabadell, El Palmar, Barcelona, Madrid

2017-12-18

Recruiting

Registry for Patients With Lipodystrophy

NCT03553420Lipodystrophy Acquired, Lipodystrophy Congenital

University of Ulm

Observational

5,000

Santiago de Compostela

2017-12-16

Active, closed

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049HIV Infections

DrugsRilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

1,049

Badalona, Barcelona, Córdoba, Elche Alicante, Madrid, Málaga, Santiago de Compostela, Seville

2017-10-27

Active, closed

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552Non-Small Cell Lung Cancer

DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib

Hoffmann-La Roche

Phase 2/3

1,000

L'Hospitalet de Llobregat, Santiago de Compostela, Pamplona, Alicante, Barcelona, Madrid, Málaga, Seville

2017-09-22

Active, closed

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer

DrugsCabozantinib·Tecentriq·Atezolizumab

Exelixis

Phase 1

914

Santiago de Compostela, Elche, Palma de Mallorca, Badalona, Sabadell, Jeréz de La Frontera, Pamplona, Oviedo

2017-09-05

Active, closed

Personalized Therapy Study - Attain Stability Quad Post-Approval Study

NCT04024943Heart Failure

Medtronic

Observational

1,092

A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago de Compostela, Valladolid

2017-08-21

Active, closed

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997Breast Cancer

DrugAbemaciclib

Eli Lilly and Company

Phase 3

5,637

Córdoba, Barcelona, Santiago de Compostela, Lleida, Pozuelo de Alarcón, Alcorcón, Madrid, Málaga

2017-07-12

Active, closed

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

146

Santiago de Compostela, Palma de Mallorca, Badalona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville, Valencia

2017-06-26

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

A Coruña, Santiago de Compostela, Santander, Las Palmas de Gran Canaria, Barcelona, Córdoba, Madrid, Salamanca

2017-01-31

Active, closed

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022Prostate Cancer

DrugsLeuprolide Acetate·Xtandi·Abiraterone acetate·Enzalutamide

Astellas Pharma Global Development, Inc.

Phase 2

900

Barcelona, Girona, Madrid, Pamplona, Salamanca, Santiago de Compostela

2016-12-22

Active, closed

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052Infection, Human Immunodeficiency Virus, HIV Infections

Drugs2 NRTIs·Cabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine

ViiV Healthcare

Phase 3

618

Badalona, Barcelona, Córdoba, Elche Alicante, Madrid, Málaga, Santiago de Compostela, Seville

2016-10-28

Recruiting

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

NCT02716246MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III

Ultragenyx Pharmaceutical Inc

Phase 2/3

Barcelona, Santiago de Compostela

2016-04-25

Active, closed

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284Neoplasms

DrugDostarlimab

Tesaro, Inc.

Phase 1

729

Santiago de Compostela, Barcelona, Girona, Madrid, Málaga, Murcia, Pamplona, Santander

2016-03-07

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Santander, A Coruña, Córdoba, Santiago de Compostela

2015-12-01

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Badajoz, Badalona, Barcelona, Elche(Alicante), Madrid, Pozuelo de Alarcón, Santiago de Compostela, Seville

2015-11-02

Active, closed

Post Market Clinical Follow Up of LEGION™ Primary TKS With VERILAST™

NCT02380092Degenerative Joint Disease

Smith & Nephew, Inc.

Observational

163

Santiago de Compostela

2015-09

Active, closed

Micra Transcatheter Pacing System Post-Approval Registry

NCT02536118Bradycardia

Medtronic

Observational

3,100

A Coruña, Barcelona, Santiago de Compostela, Toledo, Vitoria-Gasteiz

2015-07

Active, closed

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597Urothelial Cancer

DrugsErdafitinib·Midazolam·Metformin

Janssen Research & Development, LLC

Phase 2

239

Badalona, Barcelona, Madrid, Málaga, Pamplona, Sabadell, Santander, Santiago de Compostela

2015-04-22

Active, closed

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsLupron·Eligard·Leuprorelin·Xtandi

Pfizer

Phase 3

1,068

Palma de Mallorca, Manresa, Santiago de Compostela, Barcelona, Cadiz, Girona, Madrid, Ourense

2014-12-17

Active, closed

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362Crohn's Disease

AbbVie

Observational

1,446

A Coruña, Ferrol, Santiago de Compostela, Palma de Mallorca, Badalona, Esplugues de Llobregat, Sabadell, Leganés

2014-08-28

Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2

Alexion Pharmaceuticals, Inc.

Observational

300

Santiago de Compostela, Barakaldo, Logroño, Burela de Cabo, Málaga, Oviedo, Reus, A Coruña

2013-05-30

Active, closed

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561Ulcerative Colitis (UC)

AbbVie

Observational

8,250

A Coruña, Ferrol, Santiago de Compostela, Elche, Sant Joan d'Alacant, Manacor, Palma de Mallorca, Badalona

2013-04-29

Active, closed

Psoriasis Longitudinal Assessment and Registry

NCT00508547Psoriasis

Janssen Scientific Affairs, LLC

Observational

20,167

Alcalá de Henares, Bilbao, Granada, Madrid, Majadahonda, Murcia, Salamanca, Santiago de Compostela

2007-06-21

Recruiting

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

NCT02832245Venous Thromboembolism

Manuel Monreal

Observational

120,000

A Coruña, Cee, Ferrol, Ribeira, Santiago de Compostela, Albacete, Alicante, Elche

2001-03

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-spain/city/santiago-de-compostela

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 385 of those studies with a site in Santiago de Compostela.

How many clinical trials are recruiting in Santiago de Compostela?

173 of the 385 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 18 have not yet opened recruitment, 183 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Santiago de Compostela), 385 studies
Phase	Studies	Recruiting	Share
Phase 3	186	78	48.3%
Phase 2	78	35	20.3%
Observational	43	21	11.2%
Not applicable	28	13	7.3%
Phase 2/3	17	13	4.4%
Phase 1/2	13	7	3.4%
Phase 1	10	5	2.6%
Phase 4	8	1	2.1%
Early Phase 1	2	0	0.5%

Most active sponsors

Lead sponsors with the most studies (Santiago de Compostela)
Lead sponsor	Studies	Recruiting
AstraZeneca	21	8
AbbVie	18	5
Pfizer	18	12
Hoffmann-La Roche	16	5
Janssen Research & Development, LLC	16	10
Merck Sharp & Dohme LLC	16	7
Sanofi	11	3
Regeneron Pharmaceuticals	10	7
University of Santiago de Compostela	10	2
Bristol-Myers Squibb	9	4

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.